The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...
As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective alternatives for patients who respond inadequately to standard first-line treatment ...
What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...
The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results